Loading organizations...
§ Private Profile · Beijing, China
Patme Biotechnology is a high-tech animal health company focusing on innovative pet drugs.
Patme Biotechnology operates as a high-tech animal health company, with its primary focus centered on the research and development of innovative pet drugs. Headquartered in Beijing, China, the company is positioned within a dynamic biotechnology landscape, contributing to advancements in veterinary pharmaceutical solutions. Its strategic emphasis is on leveraging technology to create new treatments and improve existing ones for companion animals.
Patme Biotechnology focuses on the development of innovative pet drugs, operating within the high-tech animal health sector to advance veterinary pharmaceutical solutions.
Patme Biotechnology focuses on the development of innovative pet drugs, operating within the high-tech animal health sector to advance veterinary pharmaceutical solutions.
Patme Biotechnology most recently raised Series A in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 9, 2026 | Series A | — | TriWise Capital | Announced |
The company's work in innovative pet drugs suggests a commitment to addressing unmet needs within the animal health sector. This involves a process of scientific inquiry, preclinical testing, and potentially clinical trials to ensure the efficacy and safety of its pharmaceutical products. The objective is to enhance the quality of life for pets by providing advanced medical interventions.
Patme Biotechnology has successfully completed a Series A funding round. This early-stage investment is a significant milestone, providing capital to fuel the company's operational growth, expand its research and development capabilities, and advance its pipeline of pet drug candidates. Such funding typically supports the transition from initial concept to more robust product development and market preparation.
As a startup in the animal health industry, Patme Biotechnology's activities are integral to the broader ecosystem of veterinary medicine. Its location in Beijing, China, places it within a major hub for technological innovation and scientific research, potentially facilitating access to talent, resources, and a substantial market for its specialized products. The company's trajectory is aligned with the increasing demand for sophisticated animal care solutions globally.